Metraipolis › archive › dc_950c111baf2d
Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy — Europe PMC PMID:41685294
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41685294
- DOI
- 10.3389/fonc.2025.1652522
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T11:28:22.150Z
- SHA-256 of the archived text
9ab4ffdd7d8be215ec3b24368a026b69027518f17774dde23e33aab45f984ebc- Stable URL of this page
https://metraipolis.com/documento/dc_950c111baf2d
How to cite
Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy — Europe PMC PMID:41685294 — Europe PMC (en), https://europepmc.org/article/MED/41685294 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_950c111baf2d (Metraipolis archive dc_950c111baf2d, sha256 9ab4ffdd7d8be215ec3b24368a026b69027518f17774dde23e33aab45f984ebc)
BibTeX
@misc{dc950c111baf2d,
title = {Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy — Europe PMC PMID:41685294},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41685294},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_950c111baf2d; sha256 9ab4ffdd7d8be215ec3b24368a026b69027518f17774dde23e33aab45f984ebc},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41685294. Agents can read the archived copy with the MCP tool read_document.